JNJ Trading at 39.1% Premium to Intrinsic Value Despite Strong Dividend Yield
Johnson & Johnson's (NYSE: JNJ) stock has been deemed significantly overvalued by GuruFocus, trading at 39.1% above its intrinsic value. Despite this, the company offers a sustainable and steadily growing dividend, with a current yield of 2.0% and a payout ratio of approximately 50%. The FDA recently authorized Stelara for use in children aged two and older with moderately to severely active ulcerative colitis, expanding the medication's pediatric indications.
The approval is based on clinical data extrapolated from adult studies and pediatric safety and pharmacokinetic profiles. Johnson & Johnson's immunology portfolio has been growing, and this decision underscores the company's commitment to expanding treatment options in inflammatory bowel diseases. The stock's valuation presents a contrasting picture, with JNJ's intrinsic value estimated at $192.73 per share, according to GuruFocus' GF Value metric.
JNJ's financial health and profitability are strong, reflected by its 83/100 GF Score. However, momentum is a relative weakness, and the company's valuation and growth are considered moderate. Insiders have been selling shares over the past year, totaling $155.7 million in value, while only $0.3 million worth of shares were purchased.